ReviewFrontiers in oncology2020
Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04687176 (Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Patients with high-risk acute promyelocytic leukemia need maintenance therapy for 1 year - the CONS.Haematologica · 2025Article
- [The cure for acute promyelocytic leukemia and China's contributions].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.Blood advances · 2025Article
- Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome.Blood advances · 2025Observational
- The Potential Use of Arsenic Trioxide in the Treatment of Systemic Lupus Erythematosus.International journal of molecular sciences · 2024Review
- A Leukemic Target with a Thousand Faces: The Mitochondria.International journal of molecular sciences · 2023Review
- An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications.Cell death discovery · 2023Review
- Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021.BMC cancer · 2023Article
- Editorial: Acute promyelocytic leukemia - towards a chemotherapy-free approach to cure in all patients, Volume II.Frontiers in oncology · 2023Article
- The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases.Pharmaceutics · 2022Review
- Article
- Targeted Drug Delivery for Chronic Lymphocytic Leukemia.Pharmaceutical research · 2022Review
- Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond.Frontiers in oncology · 2022Review
- A practical strategy to subcutaneous administeredAsian journal of pharmaceutical sciences · 2021Article
- Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study.Blood advances · 2021Article
- Mitochondrial metabolism as a target for acute myeloid leukemia treatment.Cancer & metabolism · 2021Review
- Pharmacokinetic Characteristics, Tissue Bioaccumulation and Toxicity Profiles of Oral Arsenic Trioxide in Rats: Implications for the Treatment and Risk Assessment of Acute Promyelocytic Leukemia.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various forms of arsenic were used in China and elsewhere for over 5,000 years. Following the initial success of intravenous arsenic trioxide (i.v. As
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.